Menu
Search
|

Menu

Close
X

Innoviva Inc INVA.OQ (NASDAQ Stock Exchange Global Select Market)

14.16 USD
-0.02 (-0.14%)
As of 4:00 PM EDT
chart
Previous Close 14.18
Open 14.25
Volume 116,872
3m Avg Volume 360,952
Today’s High 14.40
Today’s Low 14.13
52 Week High 20.53
52 Week Low 13.27
Shares Outstanding (mil) 101.18
Market Capitalization (mil) 1,434.72
Forward P/E 4.07
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
261
FY17
217
FY16
134
EPS (USD)
FY18
3.486
FY17
1.120
FY16
0.441
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
4.07
41.05
Price to Sales (TTM)
vs sector
5.50
8.91
Price to Book (MRQ)
vs sector
9.33
4.65
Price to Cash Flow (TTM)
vs sector
3.41
28.95
Total Debt to Equity (MRQ)
vs sector
249.28
17.48
LT Debt to Equity (MRQ)
vs sector
249.28
13.83
Return on Investment (TTM)
vs sector
93.47
12.19
Return on Equity (TTM)
vs sector
--
13.29

EXECUTIVE LEADERSHIP

William Waltrip
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Geoffrey Hulme
Interim Principal Executive Officer, Since 2018
Salary: --
Bonus: --
Marianne Zhen
Chief Accounting Officer, Since 2018
Salary: --
Bonus: --
Mark DiPaolo
Director, Since 2018
Salary: --
Bonus: --
Jules Haimovitz
Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

2000 Sierra Point Pkwy Ste 500
BRISBANE   CA   94005-1830

Phone: +1650.2389600

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

SPONSORED STORIES